The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Experience with gemtuzumab ozogamycin (“mylotarg”) and all-trans retinoic acid in untreated acute promyelocytic leukemia
Open accessAbstract
We administered gemtuzumab ozogamycin (“mylotarg”; 9 mg/m2 day 1 or 5) and all-trans retinoic acid (ATRA) to 19 patients with untreated acute promyelocytic leukemia (APL). There were 3 patients who also received idarubicin because of a white blood cell (WBC) count of more than 30 000/μL. In complete remission (CR), patients were to receive 8 courses of mylotarg (9 mg/m2 every 4 to 5 weeks) and ATRA; idarubicin was added only for persistent or recurrent polymerase chain reaction (PCR) positivity. The CR rate was 16/19 (84%). All 12 patients tested to date were PCR-negative 2 to 4 months from CR date; none of the 7 patients evaluated subsequently have reverted to PCR positivity (median follow-up in CR was 5 months, up to 14 months). Mylotarg was well tolerated. A median of 5 post-CR courses have been given to date with 3 patients having currently received 8 post-CR courses, and 4 patients receiving 7 post-CR courses. Mylotarg appears active in APL, and repeated administration is feasible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estey, E. H., Giles, F. J., Kantarjian, H., O’Brien, S., Cortes, J., Freireich, E. J., Lopez-Berestein, G., & Keating, M. (1999) · Blood · doi:10.1182/blood.v94.7.2230.419k05_2230_2235 · Cited by 105
Self-citation
Cited by
Sanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., et al. (2009) · Blood · doi:10.1182/blood-2008-04-150250 · Cited by 947
Self-citationBiology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update
Pui, C.-H., Carroll, W. L., Meshinchi, S., & Arceci, R. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7405 · Cited by 842
Burnett, A. K., Russell, N. H., Hills, R. K., Bowen, D., Kell, J., Knapper, S., Morgan, Y. G., Lok, J., Grech, A., Jones, G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00193-x · Cited by 534
Lazo, G., Kantarjian, H., Estey, E., Thomas, D., O'Brien, S., & Cortes, J. (2003) · Cancer · doi:10.1002/cncr.11314 · Cited by 494
Self-citationEstey, E., Garcia-Manero, G., Ferrajoli, A., Faderl, S., Verstovsek, S., Jones, D., & Kantarjian, H. (2006) · Blood · doi:10.1182/blood-2005-10-4006 · Cited by 384
Self-citation
Metadata
- Authors
- Estey, E. H., Giles, F. J., Beran, M., O'Brien, S., Pierce, S. A., Faderl, S. H., Cortes, J. E., & Kantarjian, H. M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2002-06-01
- Volume
- 99
- Issue
- 11
- Pages
- 4222-4224
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2013264080
- Cited by
- 177
- References
- 1
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Experience with gemtuzumab ozogamycin (“mylotarg”) and all-trans retinoic acid in untreated acute promyelocytic leukemia. https://app.cochat.ai/papers/10.1182/blood-2001-12-0174
- The paper
- Estey, E. H., Giles, F. J., Beran, M., O'Brien, S., Pierce, S. A., Faderl, S. H., Cortes, J. E., & Kantarjian, H. M. (2002). Experience with gemtuzumab ozogamycin (“mylotarg”) and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood. https://doi.org/10.1182/blood-2001-12-0174
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.